Tuberculosis and HIV interaction in sub-Saharan Africa: impact on patients and programmes; implications for policies

被引:70
作者
Maher, D
Harries, A
Getahun, H
机构
[1] WHO, Stop TB Dept, CH-1211 Geneva, Switzerland
[2] Minist Hlth, HIV AIDS Unit, Lilongwe, Malawi
关键词
tuberculosis; human immunodeficiency virus; acquired immunodeficiency syndrome; programmes; policies; Africa;
D O I
10.1111/j.1365-3156.2005.01456.x
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Sub-Saharan Africa carries the overwhelming share of the global burden of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) and of HIV-associated tuberculosis (TB). The impact of HIV on TB patients and programmes has implications for TB control policies. The impact on patients includes the effect of HIV on diagnosis and on the patterns of HIV-related TB, the response of HIV-infected TB patients to TB treatment, the benefits of antiretroviral therapy (ART), and the quality and continuity of care for TB patients. The impact on national TB programmes (NTPs) includes increased case load, impaired NTP performance, increased need for access to ART and difficulties in reaching TB control targets. Implications for policies include the need to promote TB and HIV/AIDS programme collaboration, aimed at improving NTP performance (TB case-finding and treatment outcomes), quality and continuity of care, and monitoring and interpretation of progress towards TB control targets. In order to provide the recommended international standard of care for TB patients, clinicians need to be aware of the impact of HIV on TB patients and programmes and the implications for the policies that provide the framework for this standard. Conversely, policy-makers need to understand the impact of HIV on TB patients and programmes. This can help to ensure a firm evidence base for TB control policies aiming at the high standard of patient care that is at the heart of TB and HIV programmes.
引用
收藏
页码:734 / 742
页数:9
相关论文
共 63 条
[1]  
AISU T, 1995, AIDS, V9, P267, DOI 10.1097/00002030-199509030-00008
[2]  
ANDERSON S, 2001, WHOCDSTB2001294
[3]  
Ängeby KAK, 2004, INT J TUBERC LUNG D, V8, P806
[4]  
[Anonymous], 2003, Treatment of tuberculosis: guidelines for national programmes, V3rd
[5]  
[Anonymous], AIDS EP UPD 2004
[6]  
[Anonymous], B INT UNION TUBERC
[7]  
[Anonymous], 2003, SCAL ANT THER RES LT
[8]   Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study [J].
Badri, M ;
Wilson, D ;
Wood, R .
LANCET, 2002, 359 (9323) :2059-2064
[9]   Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs [J].
Barry, CE ;
Slayden, RA ;
Sampson, AE ;
Lee, RE .
BIOCHEMICAL PHARMACOLOGY, 2000, 59 (03) :221-231
[10]  
Borgdorff MW, 2002, B WORLD HEALTH ORGAN, V80, P217